212 related articles for article (PubMed ID: 33503031)
1. LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan.
Okada M; Kurimoto S; Ganz F; Boehncke WH
PLoS One; 2021; 16(1):e0245954. PubMed ID: 33503031
[TBL] [Abstract][Full Text] [Related]
2. Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study.
Mease PJ; Liu C; Siegel E; Richmond H; Wu M; Chen L; Douglas K; Lockshin B
Am J Clin Dermatol; 2019 Dec; 20(6):873-880. PubMed ID: 31612380
[TBL] [Abstract][Full Text] [Related]
3. Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study.
Boehncke WH; Horváth R; Dalkiliç E; Lima SAL; Okada M; Hojnik M; Ganz F; Lubrano E
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2035-2043. PubMed ID: 32003056
[TBL] [Abstract][Full Text] [Related]
4. Clinical Specialty Setting as Determinant of Management of Psoriatic Arthritis: A Cross-Sectional Brazilian Study.
da Silva Souza C; Goldenstein-Schainberg C; Alvarenga Anti Loduca Lima SM; Spelling Gormezano N; Ferreira Magalhães R; Ranza R
J Clin Rheumatol; 2022 Apr; 28(3):120-125. PubMed ID: 35325900
[TBL] [Abstract][Full Text] [Related]
5. Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study.
Lubrano E; Delle Sedie A; Romanelli M; Chimenti MS; Bianchi L; Piaserico S; De Felice C; Graceffa D; De Andres MI; Curatolo S; Grembiale RD; Dastoli S; Arcuri C; Angileri RG; Prignano F; Bandinelli F; Baldissera E; Mercuri SR; Franchi C; Longhi M; Patrì A; Caso F; Passiu G; Montesu MA; Parisi S; Stroppiana E; di Luzio GS; Italiano G; Di Nuzzo S; Santilli D; Bigi L; Lumetti F; Agnusdei CP; Ferrucci MG; Gualberti G; Marando F; Ramonda R; Cusano F
Clin Rheumatol; 2021 Jun; 40(6):2251-2262. PubMed ID: 33155160
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
7. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
[TBL] [Abstract][Full Text] [Related]
8. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
[TBL] [Abstract][Full Text] [Related]
9. High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study.
Behrens F; Rech J; Thaçi D; Zinke S; Rothnie KJ; Oefner Daamen C; Leipe J
Mod Rheumatol; 2022 Jan; 32(1):87-95. PubMed ID: 32856975
[TBL] [Abstract][Full Text] [Related]
10. A cross-sectional questionnaire survey involving physicians for the clarification of the diagnosis and current status of therapeutic intervention of psoriatic arthritis in Japan.
Asahina A; Minami Y; Kameda H
J Dermatol; 2024 Feb; 51(2):261-270. PubMed ID: 38087804
[TBL] [Abstract][Full Text] [Related]
11. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Gossec L; Smolen JS; Ramiro S; de Wit M; Cutolo M; Dougados M; Emery P; Landewé R; Oliver S; Aletaha D; Betteridge N; Braun J; Burmester G; Cañete JD; Damjanov N; FitzGerald O; Haglund E; Helliwell P; Kvien TK; Lories R; Luger T; Maccarone M; Marzo-Ortega H; McGonagle D; McInnes IB; Olivieri I; Pavelka K; Schett G; Sieper J; van den Bosch F; Veale DJ; Wollenhaupt J; Zink A; van der Heijde D
Ann Rheum Dis; 2016 Mar; 75(3):499-510. PubMed ID: 26644232
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.
Lee MP; Lii J; Jin Y; Desai RJ; Solomon DH; Merola JF; Kim SC
Arthritis Care Res (Hoboken); 2018 May; 70(5):791-796. PubMed ID: 28804988
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic.
Luchetti MM; Benfaremo D; Campanati A; Molinelli E; Ciferri M; Cataldi S; Capeci W; Di Carlo M; Offidani AM; Salaffi F; Gabrielli A
Clin Rheumatol; 2018 Oct; 37(10):2741-2749. PubMed ID: 30056525
[TBL] [Abstract][Full Text] [Related]
14. Rheumatologists' recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients' joint symptoms.
Taylor SL; Petrie M; O'Rourke KS; Feldman SR
J Dermatolog Treat; 2009; 20(6):350-3. PubMed ID: 19878036
[TBL] [Abstract][Full Text] [Related]
15. First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine.
Jacobs ME; Pouw JN; Welsing P; Radstake TRDJ; Leijten EFA
Rheumatology (Oxford); 2021 Feb; 60(2):780-784. PubMed ID: 32797218
[TBL] [Abstract][Full Text] [Related]
16. Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance.
Walsh JA; Pei S; Burningham Z; Penmetsa G; Cannon GW; Clegg DO; Sauer BC
J Rheumatol; 2018 Mar; 45(3):430-436. PubMed ID: 29142040
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
Pontifex EK; Dissanayake K; Bursill D; Gill T
Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
[TBL] [Abstract][Full Text] [Related]
18. Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined Dermatology-Rheumatology clinic: a retrospective real-world study.
Klavdianou K; Stavropoulou M; Panagakis P; Papoutsaki M; Panagiotopoulos A; Koutsianas C; Stratigos A; Rigopoulos D; Vassilopoulos D
Rheumatol Int; 2022 Jun; 42(6):1035-1041. PubMed ID: 35435445
[TBL] [Abstract][Full Text] [Related]
19. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
[TBL] [Abstract][Full Text] [Related]
20. Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis.
Lu C; Yang F; Liu H; Dou L; Wang Y; Li H; Duan X; Wu L; Wang Y; Zhang X; Xu J; Su J; Xu D; Zhao J; Wu Q; Li M; Leng X; Zeng X;
Int J Rheum Dis; 2023 Sep; 26(9):1737-1744. PubMed ID: 37424174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
